Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 7/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21481881 | 1.00 | CRHR1 (0.42) | CRHR1CNR2CNR1CRHR2SLC6A12 | |
| SCHEMBL21506214 | 0.91 | CRHR1 (0.40) | CRHR1CNR2CNR1CRHR2MEN1 | |
| SCHEMBL21482122 | 0.91 | PRKAA2 (0.43) | CRHR1CNR2 | |
| SCHEMBL21506526 | 0.90 | DRD4 (0.41) | CRHR1CNR2CNR1SLC6A12SMN1; SMN2 | |
| SCHEMBL21482124 | 0.90 | MCHR1 (0.42) | CRHR1CNR2CNR1CRHR2 | |
| SCHEMBL21482133 | 0.89 | CNR2 (0.42) | CRHR1CNR2CNR1SLC6A12MEN1 | |
| SCHEMBL31203526 | 0.89 | PTGER4 (0.39) | CRHR1CNR2CNR1SLC6A12MEN1 | |
| SCHEMBL21458121 | 0.89 | PTGER4 (0.39) | CRHR1CNR2CNR1SLC6A12MEN1 | |
| SCHEMBL21482140 | 0.88 | CNR2 (0.44) | CRHR1CNR2CNR1CRHR2SLC6A12 | |
| SCHEMBL21482146 | 0.88 | MCHR1 (0.45) | CRHR1CNR2CNR1CRHR2SLC6A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| WO-2019204523-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | CRHR1 87/4885CNR2 3/4885CNR1 6/4885 |
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | CRHR1 87/4885CNR2 3/4885CNR1 6/4885 |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CRHR1 87/4885CNR2 3/4885CNR1 6/4885 |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CRHR1 87/4885CNR2 3/4885CNR1 6/4885 |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CRHR1 87/4885CNR2 3/4885CNR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.